Despite reported ability of WFA to target NF-kB in lymphoma models [14], microscopy analyses revealed WFA treatment did not alter subcellular distribution of NF-κB in MDS-L cells (Supplementary Figure 3A, 3B). This evidence concerns the gene NFKB1 and myelodysplastic syndrome.